Special Articles

Clinical and Translational Oncology

, Volume 13, Issue 11, pp 798-804

Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain

  • José María VieitezAffiliated withHospital Universitario Central de Asturias
  • , Rocío García-CarboneroAffiliated withInstituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío
  • , Jorge AparicioAffiliated withHospital Universitario La Fe
  • , Jaime FeliuAffiliated withHospital Universitario La Paz
  • , Encarnación González-FloresAffiliated withHospital Universitario Virgen de las Nieves
  • , Enrique GrandeAffiliated withHospital Universitario Ramón y Cajal
  • , Teresa Pérez-HoyosAffiliated withHospital de Basurto
  • , Antonieta SaludAffiliated withHospital Universitario Arnau de Vilanova
  • , Esperanza TorresAffiliated withHospital Universitario Virgen de la Victoria
    • , María ValeroAffiliated withHospital Universitario Central de AsturiasHospital Infanta Luisa
    • , Manuel Valladares-AyerbesAffiliated withHospital Universitario Central de AsturiasComplejo Hospital Universitario A Coruña
    • , Eduardo Díaz-RubioAffiliated withHospital Universitario Central de AsturiasMedical Oncology Department, Hospital Clínico Universitario San Carlos C/Prof. Martín Lagos, s/n Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Adjuvant chemotherapy is the current standard in the management of patients with localised colon cancer (CC) following curative resection. The use of oxaliplatin plus 5 fluorouracil/leucovorin (FOLFOX) or oxaliplatin plus capecitabine-based (XELOX) regimens, both approved in Europe as adjuvant treatment for stage III CC, has improved prognosis in this stage, but questions on their usefulness in high-risk stage II or elderly CC patients and on the role of some prognostic biomarkers are still pending. In April 2010, a consensus meeting on adjuvant CC treatment based on a revision of the most recent literature was held in Spain. The panel considered the use of adjuvant chemotherapy for high-risk stage II CC patients to be justified. Additionally, the more convenient administration of oral fluoropyrimidines vs. IV continuous infusion 5-FU would make XELOX a more suitable alternative for the patient. A more cautious decision should be taken when prescribing oxaliplatin treatment in patients aged ≥70.


Colorectal neoplasms Consensus Spain Antineoplastic agents Prognosis Tumour markers